sl1904b

SL1904B is an **autologous, lentiviral vector-based anti-CD19 chimeric antigen receptor (CAR) T-cell therapy** under development primarily by Hebei Senlang Biotechnology. The therapy consists of patient-derived T cells engineered to express a CAR construct containing a CD19-targeting single-chain variable fragment (scFv) from FMC63, a costimulatory domain from human CD137 (4-1BB), and the intracellular CD3ζ signaling domain. The intended primary indication is for the treatment of **relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)**, with ongoing trials also evaluating efficacy in **non-Hodgkin's lymphoma**. The proposed mechanism is direct immunologic cytotoxicity against CD19-expressing B cells, serving both as immunotherapy and gene therapy through T lymphocyte replacement[1][2][3][4][5][7].

Brand names

SL1904BSL-1904BSL 1904B

Other names

Anti-CD19 chimeric antigen receptor T-cell therapy Senl_1904BAutologous CD19-targeting CAR T cell therapyCAR-γδT cell injectionCD19 CAR-TCD-19 CAR-TCD 19 CAR-TSenl-1904BSenl1904BSenl 1904BSenl_1904B CD19 CAR-T cell therapy